Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Veracyte, Inc. (VCYT)  
$43.53 0.69 (1.61%) as of 4:30 Mon 12/15


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 88,060,000
Market Cap: 3.83(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $23.03 - $49.38
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  749
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 171,620 179,287 282,425 485,149
Total Sell Value $7,263,804 $7,496,937 $10,979,373 $17,745,637
Total People Sold 10 10 11 11
Total Sell Transactions 19 20 31 61
End Date 2025-09-14 2025-06-13 2024-12-13 2023-12-14

   
Records found: 621
  Page 1 of 25  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Eastham Karin Director   –       •      –    2025-12-05 4 AS $44.52 $908,923 D/D (20,000) 13,554 -4%     
   Eastham Karin Director   –       •      –    2025-12-05 4 OE $7.60 $155,400 D/D 20,000 33,554     -
   Stapley Marc Chief Executive Officer   •       •      –    2025-12-04 4 AS $46.90 $361,076 D/D (7,668) 318,603 -10%     
   Chambers Rebecca Chief Financial Officer   •       –      –    2025-12-04 4 AS $46.61 $621,955 D/D (13,278) 109,496 -10%     
   Leite John Chief Commercial Officer-CLIA   •       –      –    2025-12-04 4 AS $47.51 $60,718 D/D (1,278) 82,113 -10%     
   Mcguire Annie SVP, General Counsel   •       –      –    2025-12-04 4 AS $47.10 $67,261 D/D (1,422) 78,499 -10%     
   Febbo Phillip G. Chief Scientific & Med Officer   •       –      –    2025-12-02 4 D $46.16 $136,403 D/D (2,955) 89,486     -
   Stapley Marc Chief Executive Officer   •       •      –    2025-12-02 4 D $46.16 $365,310 D/D (7,914) 326,271     -
   Chambers Rebecca Chief Financial Officer   •       –      –    2025-12-02 4 D $46.16 $156,205 D/D (3,384) 122,774     -
   Wygant Jonathan VP, Chief Accounting Officer   •       –      –    2025-12-02 4 D $46.16 $61,162 D/D (1,325) 37,420     -
   Leite John Chief Commercial Officer-CLIA   •       –      –    2025-12-02 4 D $46.16 $133,864 D/D (2,900) 83,391     -
   Mcguire Annie SVP, General Counsel   •       –      –    2025-12-02 4 D $46.16 $140,880 D/D (3,052) 79,921     -
   Jones Evan/ Fa Director   –       •      –    2025-11-25 4 AS $50.25 $55,576 D/D (1,106) 29,362 -13%     
   Leite John Chief Commercial Officer-CLIA   •       –      –    2025-11-25 4 AS $50.00 $140,400 D/D (2,808) 86,291 -13%     
   Holstein Jens Director   –       •      –    2025-11-20 4 AS $40.95 $423,563 D/D (10,000) 27,199 5%     
   Wygant Jonathan VP, Chief Accounting Officer   •       –      –    2025-11-10 4 S $42.33 $215,978 D/D (5,102) 38,745 -1%     
   Wygant Jonathan VP, Chief Accounting Officer   •       –      –    2025-11-07 4 S $40.21 $233,929 D/D (5,818) 43,847 -3%     
   Eastham Karin Director   –       •      –    2025-11-05 4 AS $40.02 $387,191 D/D (9,674) 13,554 -7%     
   Chambers Rebecca Chief Financial Officer   •       –      –    2025-11-05 4 AS $41.00 $287,000 D/D (7,000) 126,158 -7%     
   Jones Evan/ Fa Director   –       •      –    2025-11-05 4 AS $41.74 $1,946,288 D/D (43,196) 30,468 -7%     
   Jones Evan/ Fa Director   –       •      –    2025-11-05 4 OE $5.28 $208,200 D/D 30,000 73,664     -
   Mcguire Annie SVP, General Counsel   •       –      –    2025-11-05 4 AS $40.00 $258,640 D/D (6,466) 82,973 -7%     
   Wygant Jonathan VP, Chief Accounting Officer   •       –      –    2025-10-28 4 A $0.00 $0 D/D 2,886 49,665     -
   Febbo Phillip G. Chief Scientific & Med Officer   •       –      –    2025-10-06 4 AS $36.02 $300,709 D/D (8,349) 92,441 19%     
   Epstein Robert S Director   –       •      –    2025-10-01 4 AS $35.08 $753,204 D/D (21,473) 62,446 18%     
  621 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 25
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us